Adding chemo to Tagrisso slows form of lung cancer

11 September 2023
tagrisso_big

The addition of chemotherapy to Tagrisso (osimertinib) extended median progression-free survival by nearly nine months in EGFR-mutated advanced lung cancer in the FLAURA2 Phase III trial.

This combination reduced the risk of disease progression by 38% versus Tagrisso monotherapy, the current first-line global standard of care.

"With these convincing data, patients may soon have a choice of two highly effective osimertinib-based treatment options in this advanced disease setting"By investigator assessment, the combination extended median progression-free survival (PFS) by 8.8 months versus the AstraZeneca (LSE: AZN) drug alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology